Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Monopar Therapeutics Inc ( (MNPR) ) has provided an update.
On May 19, 2026, Monopar Therapeutics reported that Hepatology Communications published Phase 2 data showing its investigational drug ALXN1840 (tiomolibdate choline) significantly improved copper balance in nine patients with Wilson disease. The open-label study, conducted in the U.K. and New Zealand in patients previously treated for an average of 16 years, found rapid, statistically significant and sustained reductions in daily copper balance driven by increased fecal copper excretion, with ALXN1840 generally well tolerated and no serious adverse events.
The publication detailed key metrics, including a cumulative mean copper balance decrease of -6.08 mg over 21 days, meaningful daily balance reductions, about a 50% rise in the fecal copper output-to-intake ratio, and immediate increases in plasma copper consistent with mobilization via albumin tripartite complexes. These results, which align with prior Phase 3 findings of superior copper mobilization versus standard of care, suggest ALXN1840 can eliminate substantial residual copper in long-treated Wilson disease patients, reinforcing Monopar’s positioning in rare liver disorders and potentially altering long-term management for this patient population.
The most recent analyst rating on (MNPR) stock is a Buy with a $59.27 price target. To see the full list of analyst forecasts on Monopar Therapeutics Inc stock, see the MNPR Stock Forecast page.
Spark’s Take on MNPR Stock
According to Spark, TipRanks’ AI Analyst, MNPR is a Neutral.
The score is held back primarily by weak financial performance (no revenue, worsening losses, and accelerating cash burn), despite low leverage. Offsetting factors include constructive near-term technicals and positive corporate events driven by strong Phase 3 data and commercialization-focused leadership hiring, while valuation is constrained by negative earnings and no dividend support.
To see Spark’s full report on MNPR stock, click here.
More about Monopar Therapeutics Inc
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs. Its pipeline includes late-stage ALXN1840 for Wilson disease and radiopharmaceutical programs such as MNPR-101-Zr for imaging advanced cancers and MNPR-101-Lu and MNPR-101-Ac for treating advanced cancers.
Average Trading Volume: 186,418
Technical Sentiment Signal: Buy
Current Market Cap: $397.1M
See more data about MNPR stock on TipRanks’ Stock Analysis page.